Heart Failure Subtypes and Cardiomyopathies in Women

Heart failure affects over 2.6 million women and 3.4 million men in the United States with known sex differences in epidemiology, management, response to treatment, and outcomes across a wide spectrum of cardiomyopathies that include peripartum cardiomyopathy, hypertrophic cardiomyopathy, stress cardiomyopathy, cardiac amyloidosis, and sarcoidosis. Some of these sex-specific considerations are driven by the cellular effects of sex hormones on the renin-angiotensin-aldosterone system, endothelial response to injury, vascular aging, and left ventricular remodeling. Other sex differences are perpetuated by implicit bias leading to undertreatment and underrepresentation in clinical trials. The goal of this narrative review is to comprehensively examine the existing literature over the last decade regarding sex differences in various heart failure syndromes from pathophysiological insights to clinical practice.

[1]  Giuseppe Famularo,et al.  Transthyretin amyloid cardiomyopathy. , 2023, The American journal of the medical sciences.

[2]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[3]  Akshay S. Desai,et al.  Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial , 2021, The Lancet.

[4]  M. Mack,et al.  Sex-Specific Outcomes of Transcatheter Mitral-Valve Repair and Medical Therapy for Mitral Regurgitation in Heart Failure. , 2021, JACC. Heart failure.

[5]  C. Rapezzi,et al.  Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS. , 2021, JACC. Heart failure.

[6]  D. Holmes,et al.  Sex Differences in Outcomes Following Left Atrial Appendage Closure. , 2021, Mayo Clinic proceedings.

[7]  M. Costanzo,et al.  Remote Hemodynamic Monitoring Equally Reduces Heart Failure Hospitalizations in Women and Men in Clinical Practice , 2021, Circulation. Heart failure.

[8]  F. Zannad,et al.  Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure , 2021, JACC. Heart failure.

[9]  S. Blankenberg,et al.  Sex-Related Clinical Characteristics and Outcomes of Patients Undergoing Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation. , 2021, JACC. Cardiovascular interventions.

[10]  V. Kouranos,et al.  Cardiac sarcoidosis: state-of-the-art review , 2021, Heart.

[11]  P. Heerdt,et al.  Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction. , 2020, Chest.

[12]  J. Lasala,et al.  Sociodemographic differences in utilization and outcomes for temporary cardiovascular mechanical support in the setting of cardiogenic shock. , 2020, American heart journal.

[13]  C. Yancy,et al.  Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review , 2020, European journal of heart failure.

[14]  Y. Ko,et al.  Gender Differences in Mortality After Left Ventricular Assist Device Implant: A Causal Mediation Analysis Approach. , 2020, ASAIO journal.

[15]  Z. Fayad,et al.  Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[16]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure , 2020, New England Journal of Medicine.

[17]  D. Burkhoff,et al.  Sex Differences in the Phenotype of Transthyretin Cardiac Amyloidosis due to Val122Ile Mutation: Insights from Non-Invasive Pressure-Volume Analysis. , 2020, Journal of cardiac failure.

[18]  A. Volgman,et al.  Sex Differences in Takotsubo Syndrome: A Narrative Review. , 2020, Journal of women's health.

[19]  Adam Castaño,et al.  Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges , 2020, Heart Failure Reviews.

[20]  Song Zhao,et al.  Letter by Wu and Zhao Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF". , 2020, Circulation.

[21]  Sanjiv J. Shah,et al.  Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. , 2020, JACC. Heart failure.

[22]  Mark P. MacEachern,et al.  Extracorporeal Life Support in Pregnancy: A Systematic Review , 2020, Journal of the American Heart Association.

[23]  R. Falk,et al.  Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week. , 2020, Journal of the American College of Cardiology.

[24]  L. Lund,et al.  Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease , 2020, European journal of heart failure.

[25]  S. Solomon,et al.  Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials , 2020, The Lancet.

[26]  M. Wheeler,et al.  Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. , 2020, JACC. Heart failure.

[27]  S. Patil,et al.  Gender Differences in Rates of Arrhythmias, Cardiac Implantable Electronic Devices, and Diagnostic Modalities Among Sarcoidosis Patients , 2020, Cureus.

[28]  E. Depasquale,et al.  Heart Transplantation Outcomes in Adults with Postpartum Cardiomyopathy. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[29]  M. Clowse,et al.  Antirheumatic medications in pregnancy and breastfeeding. , 2020, Current opinion in rheumatology.

[30]  G. Kararigas,et al.  Menopause-Related Estrogen Decrease and the Pathogenesis of HFpEF: JACC Review Topic of the Week. , 2020, Journal of the American College of Cardiology.

[31]  M. Barton,et al.  Heart Failure With Preserved Ejection Fraction in Women , 2020, JACC. Basic to translational science.

[32]  D. Hilfiker-Kleiner,et al.  Peripartum cardiomyopathy: basic mechanisms and hope for new therapies. , 2020, Cardiovascular research.

[33]  S. Solomon,et al.  Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials , 2020, European journal of heart failure.

[34]  M. Dweck,et al.  Sex differences in aortic stenosis: from pathophysiology to treatment , 2020, Expert review of cardiovascular therapy.

[35]  S. Goland,et al.  Peripartum Cardiomyopathy: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[36]  Brandon C. Benefield,et al.  Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension , 2020, ESC heart failure.

[37]  S. Solomon,et al.  Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. , 2019, JACC. Heart failure.

[38]  C. Grines,et al.  Use of Impella heart pump for management of women with peripartum cardiogenic shock , 2019, Clinical cardiology.

[39]  R. Falk,et al.  Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. , 2019, JACC. Heart failure.

[40]  H. D. den Ruijter,et al.  Estrogen Contributions to Microvascular Dysfunction Evolving to Heart Failure With Preserved Ejection Fraction , 2019, Front. Endocrinol..

[41]  A. Petrie,et al.  Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. , 2019, Circulation.

[42]  M. Michels,et al.  Sex differences in hypertrophic cardiomyopathy: new insights , 2019, Current opinion in cardiology.

[43]  J. Lindenfeld,et al.  Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. , 2019, JACC. Heart failure.

[44]  Y. Naka,et al.  Sex-Related Differences in Use and Outcomes of Left Ventricular Assist Devices as Bridge to Transplantation. , 2019, JACC. Heart failure.

[45]  J. Mariani,et al.  Sex Differences in Heart Failure With Preserved Ejection Fraction Pathophysiology: A Detailed Invasive Hemodynamic and Echocardiographic Analysis. , 2019, JACC. Heart failure.

[46]  M. Kürtüncü,et al.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2019, Turkish Journal Of Neurology.

[47]  E. Hsich,et al.  Heart Failure with Reduced Ejection Fraction in Women: Epidemiology, Outcomes, and Treatment. , 2019, Heart failure clinics.

[48]  Akshay S. Desai,et al.  Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. , 2019, Journal of the American College of Cardiology.

[49]  D. Pennell,et al.  Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial , 2019, The Lancet.

[50]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[51]  Susanna Price,et al.  2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. , 2018, European heart journal.

[52]  E. Arkema,et al.  Epidemiology of sarcoidosis: current findings and future directions , 2018, Therapeutic advances in chronic disease.

[53]  V. Melenovský,et al.  Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction , 2018, European heart journal.

[54]  Sanjiv J. Shah,et al.  The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. , 2018, JACC. Heart failure.

[55]  C. Poggesi,et al.  Sex Differences at the Time of Myectomy in Hypertrophic Cardiomyopathy , 2018, Circulation. Heart failure.

[56]  Jeroen J. Bax,et al.  International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology , 2018, European heart journal.

[57]  G. Hindricks,et al.  Prevalence of clinically apparent hypertrophic cardiomyopathy in Germany—An analysis of over 5 million patients , 2018, PloS one.

[58]  C. Ayers,et al.  Sex and Race Differences in Lifetime Risk of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction , 2018, Circulation.

[59]  J. Mascherbauer,et al.  Gender-related differences in heart failure with preserved ejection fraction , 2018, Scientific Reports.

[60]  B. Gersh,et al.  Women with hypertrophic cardiomyopathy have worse survival , 2017, European heart journal.

[61]  M. Hanna,et al.  Cardiac amyloidosis: An update on diagnosis and treatment , 2017, Cleveland Clinic Journal of Medicine.

[62]  M. Elovitz,et al.  Comparison of Clinical Characteristics and Outcomes of Peripartum Cardiomyopathy Between African American and Non–African American Women , 2017, JAMA cardiology.

[63]  Kevin L. Thomas,et al.  Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes , 2017, American heart journal.

[64]  Yang Song,et al.  Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR ®) PINNACLE Registry , 2017, Journal of the American Heart Association.

[65]  D. Conen,et al.  Sex differences in outcomes of primary prevention implantable cardioverter-defibrillator therapy: combined registry data from eleven European countries , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[66]  C. Rapezzi,et al.  Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths , 2017, European heart journal.

[67]  L. Lund,et al.  Association between demographic, organizational, clinical, and socio‐economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry , 2017, European journal of heart failure.

[68]  Jagmeet P. Singh,et al.  Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator , 2017, European heart journal.

[69]  G. Aurigemma,et al.  Reproductive History of Women With Takotsubo Cardiomyopathy. , 2016, The American journal of cardiology.

[70]  M. Maurer,et al.  Transthyretin Cardiac Amyloidosis in Older Americans. , 2016, Journal of cardiac failure.

[71]  J. Manson,et al.  Risk Factors for Incident Hospitalized Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Postmenopausal Women , 2016, Circulation. Heart failure.

[72]  R. Falk,et al.  AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. , 2016, Journal of the American College of Cardiology.

[73]  J. Seidman,et al.  Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. , 2016, The New England journal of medicine.

[74]  Deepak L. Bhatt,et al.  Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings from the Get With The Guidelines-Heart Failure Program , 2016, Circulation.

[75]  J. Mascherbauer,et al.  Functional Status, Pulmonary Artery Pressure, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. , 2016, Journal of the American College of Cardiology.

[76]  Sanjiv J. Shah,et al.  Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). , 2016, Journal of the American College of Cardiology.

[77]  Sanjiv J Shah,et al.  Predicting Heart Failure With Preserved and Reduced Ejection Fraction: The International Collaboration on Heart Failure Subtypes. , 2016, Circulation. Heart failure.

[78]  Dhanunjaya R. Lakkireddy,et al.  Cardiac Resynchronization Therapy: US Trends and Disparities in Utilization and Outcomes , 2016, Circulation. Arrhythmia and electrophysiology.

[79]  Susan Cheng,et al.  Sex differences in cardiovascular ageing , 2016, Heart.

[80]  R. Fischer-Betz,et al.  The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation , 2016, Annals of the rheumatic diseases.

[81]  P. Noseworthy,et al.  Gender, Racial, and Health Insurance Differences in the Trend of Implantable Cardioverter‐Defibrillator (ICD) Utilization: A United States Experience Over the Last Decade , 2016, Clinical cardiology.

[82]  L. Stevenson,et al.  Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial , 2016, The Lancet.

[83]  P. Westermark,et al.  Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition , 2015, PloS one.

[84]  R. Wachter,et al.  Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy , 2015, European journal of heart failure.

[85]  Frank M. Bogun,et al.  Cardiac Sarcoidosis , 2015, Circulation.

[86]  Jeroen J. Bax,et al.  Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. , 2015, The New England journal of medicine.

[87]  Christine H Morton,et al.  Pregnancy-related cardiovascular deaths in California: beyond peripartum cardiomyopathy. , 2015, American journal of obstetrics and gynecology.

[88]  G. Ewald,et al.  Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). , 2015, Journal of the American College of Cardiology.

[89]  A. Russo,et al.  Gender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: Findings from the National Cardiovascular Data Registry (NCDR). , 2015, American heart journal.

[90]  J. Killian,et al.  A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. , 2015, JAMA internal medicine.

[91]  J. Airaksinen,et al.  Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. , 2015, Circulation.

[92]  W. Edwards,et al.  Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction , 2015, Circulation.

[93]  V. Roger,et al.  Right Ventricular Function in Heart Failure With Preserved Ejection Fraction: A Community-Based Study , 2014, Circulation.

[94]  U. Elkayam Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. , 2014, Journal of the American College of Cardiology.

[95]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[96]  David G. Strauss,et al.  Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. , 2014, JAMA internal medicine.

[97]  J. Healey,et al.  Atrioventricular Block as the Initial Manifestation of Cardiac Sarcoidosis in Middle‐Aged Adults , 2014, Journal of cardiovascular electrophysiology.

[98]  Amit R. Patel,et al.  HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. , 2014, Heart rhythm.

[99]  P. Tchou,et al.  Probability and magnitude of response to cardiac resynchronization therapy according to QRS duration and gender in nonischemic cardiomyopathy and LBBB. , 2014, Heart rhythm.

[100]  S. Solomon,et al.  Sex‐specific cardiovascular structure and function in heart failure with preserved ejection fraction , 2014, European journal of heart failure.

[101]  W. Edwards,et al.  Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. , 2014, JACC. Heart failure.

[102]  Hao Wang,et al.  Role of estrogen in diastolic dysfunction. , 2014, American journal of physiology. Heart and circulatory physiology.

[103]  Deepak L. Bhatt,et al.  Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry. , 2013, American heart journal.

[104]  L. Padeletti,et al.  Gender‐Related Safety and Efficacy of Cardiac Resynchronization Therapy , 2013, Clinical cardiology.

[105]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[106]  Sanjiv J. Shah,et al.  The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction , 2013, Current Heart Failure Reports.

[107]  P. Nery,et al.  Corticosteroid therapy for cardiac sarcoidosis: a systematic review. , 2013, The Canadian journal of cardiology.

[108]  K. Sakata,et al.  Gender Differences in Patients with Takotsubo Cardiomyopathy: Multi-Center Registry from Tokyo CCU Network , 2013, PloS one.

[109]  U. Sechtem,et al.  Gender differences in the manifestation of tako-tsubo cardiomyopathy. , 2013, International journal of cardiology.

[110]  J. Wisnivesky,et al.  Supraventricular arrhythmias in patients with cardiac sarcoidosis prevalence, predictors, and clinical implications. , 2013, Chest.

[111]  D. Levy,et al.  Predictors of New-Onset Heart Failure: Differences in Preserved Versus Reduced Ejection Fraction , 2013, Circulation. Heart failure.

[112]  D. Lackland,et al.  The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. , 2012, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[113]  K. Swedberg,et al.  Important Differences in Mode of Death Between Men and Women With Heart Failure Who Would Qualify for a Primary Prevention Implantable Cardioverter-Defibrillator , 2012, Circulation.

[114]  R. McKelvie,et al.  Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction: The Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial , 2012, Circulation. Heart failure.

[115]  V. Roger,et al.  Gender Differences in the Pathophysiology, Clinical Presentation, and Outcomes of Ischemic Heart Failure , 2012, Current Heart Failure Reports.

[116]  Adrian F Hernandez,et al.  Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Therapies, and Outcomes , 2012, Circulation.

[117]  R. Wachter,et al.  Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. , 2012, Journal of the American Society of Hypertension : JASH.

[118]  Kevin L. Thomas,et al.  Trends in Use of Implantable Cardioverter-Defibrillator Therapy Among Patients Hospitalized for Heart Failure: Have the Previously Observed Sex and Racial Disparities Changed Over Time? , 2012, Circulation.

[119]  P. Austin,et al.  Sex Differences in Implantable Cardioverter-Defibrillator Outcomes: Findings From a Prospective Defibrillator Database , 2012, Annals of Internal Medicine.

[120]  Mike Kirby,et al.  ESC Guidelines on the Management of Cardiovascular Diseases During Pregnancy , 2012 .

[121]  S. Goland,et al.  Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. , 2011, Journal of cardiac failure.

[122]  Sanjiv J. Shah,et al.  Clinical Characteristics of Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction , 2011, Circulation. Heart failure.

[123]  Sungha Park,et al.  Sex differences in central hemodynamics and their relationship to left ventricular diastolic function. , 2011, Journal of the American College of Cardiology.

[124]  L. Stevenson,et al.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.

[125]  Kevin L. Thomas,et al.  Extent of and Reasons for Nonuse of Implantable Cardioverter Defibrillator Devices in Clinical Practice Among Eligible Patients With Left Ventricular Systolic Dysfunction , 2011, Circulation. Cardiovascular quality and outcomes.

[126]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[127]  S. Mochizuki,et al.  Gender and the renin–angiotensin–aldosterone system , 2010, Fundamental & clinical pharmacology.

[128]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[129]  A. Natale,et al.  Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. , 2010, Heart rhythm.

[130]  G. Raskob,et al.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.

[131]  S. Goland,et al.  Clinical profile and predictors of complications in peripartum cardiomyopathy. , 2009, Journal of cardiac failure.

[132]  H. Ghanbari,et al.  Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. , 2009, Archives of internal medicine.

[133]  P. Austin,et al.  Evaluating sex differences in population-based utilization of implantable cardioverter-defibrillators: role of cardiac conditions and noncardiac comorbidities. , 2009, Heart rhythm.

[134]  I. Piña,et al.  Heart failure in women: a need for prospective data. , 2009, Journal of the American College of Cardiology.

[135]  A. Lerman,et al.  Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. , 2008, American heart journal.

[136]  K. Schulman,et al.  Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. , 2007, JAMA.

[137]  M. Hudson,et al.  Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure — A population study , 2007, European journal of heart failure.

[138]  Anne L. Taylor,et al.  Outcomes by gender in the African-American Heart Failure Trial. , 2006, Journal of the American College of Cardiology.

[139]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[140]  M. Drazner,et al.  Women Have Higher Left Ventricular Ejection Fractions Than Men Independent of Differences in Left Ventricular Volume: The Dallas Heart Study , 2006, Circulation.

[141]  D. Kass,et al.  Age- and Gender-Related Ventricular-Vascular Stiffening: A Community-Based Study , 2005, Circulation.

[142]  M. Link,et al.  Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[143]  U. Elkayam,et al.  Pregnancy-Associated Cardiomyopathy: Clinical Characteristics and a Comparison Between Early and Late Presentation , 2005, Circulation.

[144]  C. O'connor,et al.  Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. , 2004, Journal of the American College of Cardiology.

[145]  C. Yancy,et al.  Hormone replacement therapy is associated with improved survival in women with advanced heart failure. , 2003, Journal of the American College of Cardiology.

[146]  Paul G Shekelle,et al.  Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. , 2003, Journal of the American College of Cardiology.

[147]  G. Biondi-Zoccai,et al.  Reduced post-infarction myocardial apoptosis in women: a clue to their different clinical course? , 2003, Heart.

[148]  Harlan M Krumholz,et al.  Sex-based differences in the effect of digoxin for the treatment of heart failure. , 2002, The New England journal of medicine.

[149]  C. Fonseca,et al.  Prevalence of chronic heart failure in Southwestern Europe: the EPICA study , 2002, European journal of heart failure.

[150]  I. Piña,et al.  Metoprolol CR/XL in Female Patients With Heart Failure: Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) , 2002, Circulation.

[151]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[152]  T. Simon,et al.  Sex Differences in the Prognosis of Congestive Heart Failure: Results From the Cardiac Insufficiency Bisoprolol Study (CIBIS II) , 2001, Circulation.

[153]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[154]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[155]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[156]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[157]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[158]  A. Beale,et al.  Sex Differences in Heart Failure with Preserved Ejection Fraction Therapy: Potential Mechanisms and Clinical Implications , 2020 .

[159]  G. Lewis,et al.  Sex Differences in Cardiometabolic Traits and Determinants of Exercise Capacity in Heart Failure With Preserved Ejection Fraction. , 2019, JAMA cardiology.

[160]  C. Albert,et al.  Atrial Fibrillation and Heart Failure in Women. , 2019, Heart failure clinics.

[161]  U. Elkayam,et al.  Peripartum Cardiomyopathy. , 2016, Circulation.

[162]  K. Stergiopoulos,et al.  Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. , 2016, The New England journal of medicine.

[163]  F. Zannad Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms , 2011 .

[164]  B. Pitt,et al.  EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .